The US FDA has rejected Regeneron Pharmaceuticals’ application to manufacture its multiple myeloma drug candidate linvoseltamab, citing unresolved issues with its third-party manufacturer. While a reinspection is expected in the coming months, Regeneron said European Medicines Agency review of the drug is still ongoing. The medication is designed to treat multiple myeloma that has advanced after at least three earlier lines of therapy.
GP2GP likely to be phased out and more briefs
Te Whatu Ora plans to address risks of the outdated GP2GP electronic record system until a new digital health record launches midyear. In Western Australia,
